The present invention relates to glycolipoprotein gintonin, isolated and identified from
ginseng, as a natural medicinal-
plant-derived ligand acting on LPA1 (
lysophosphatidic acid; 1- or 2-acyl-sn-
glycerol-3-
phosphate), LPA2, LPA3, LPA4 and LPA5 receptors whose
efficacy is exhibited physiologically / pharmaceutically via an interaction with subset receptors [LPA1(edg-2), LPA2(edg-4), LPA3(edg-7), LPA4, PLA5] in the EDG (endothelial differentiation
gene) family in
G protein-coupled receptors (GPCRs) present in the
cell membranes of animals including humans. The gintonin of the present invention can be used to
advantage in the prevention and treatment of various diseases arising from reduced
calcium concentration and various physiological activities and pharmaceutical activities dependent on
calcium, since the gintonin of the present invention interacts with
LPA receptors so as to activate a series of
signal transmission processes and temporarily induce an increase in free Ca2+ in the
cytoplasm, and a temporary increase in the
intracellular calcium concentration gives rise to a temporary increase in the
intracellular calcium concentration in various organs including, inter alia, those of the
nervous system, cardiovascular
system,
endocrine system,
reproductive system, digestive
system and
immune system when the
LPA receptors are expressed, with physiological activity being exhibited.